CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

FDA Drugs (New Approvals & NDA)
Original article

BsUFA IV: Fiscal Years 2028-2032

RegulatoryNeutral
AI Analysis

Summary

The FDA User Fee Reauthorization Act of 2022 was signed into law on September 30, 2022, establishing BsUFA IV parameters for fiscal years 2028-2032. This is a routine regulatory update with no material impact on specific drug programs or companies.

Importance:2/10
Sentiment:
0.00
FDA User FeesRegulatoryBsUFA IV2028-2032

Read the original article

Published by FDA Drugs (New Approvals & NDA) on June 4, 2026 1:26 AM

Read Original